General Mills is particularly vulnerable to changing consumer preferences and health trends, given its reliance on cereal, snacks, and convenient foods (52% of fiscal 2024 sales). Losing market share ...
The "Buy Canadian" movement is sending new ripples of concern through the executive offices of U.S.-based consumer companies ...
Analysts have been eager to weigh in on the Consumer Goods sector with new ratings on Kimberly Clark (KMB – Research Report) and ...
Billionaire Dalio, head of the world's largest hedge fund, is considered a global authority on investing in China. The bank ...
The announcement that 23andMe is filing for bankruptcy and has put its genetic genealogy database up for sale has sent its ...
The U.S. Food and Drug Administration has granted approval to a new antibiotic to treat urinary tract infections in women and ...
GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...
At Tata Consumer Products, Das drives growth strategy, outcomes and profit & loss for the packaged beverages category in ...
Our writer Ken Hall evaluates two defensive dividend payers in the FTSE 100 that he thinks investors should consider buying ...
Pfizer has officially kissed goodbye to its consumer health venture by selling its final 7.3% stake in Haleon for a tidy $3.3 ...
Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon ...
Pharmaceutical Technology on MSN12d
Pfizer sells 7.3% stake in Haleon for $3.3bnThe disposal represents Pfizer's exit from its investment in Haleon, which originated from a JV formed with GSK in 2019.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback